BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther. 2001;15:1737-1744. [PMID: 11683687 DOI: 10.1046/j.1365-2036.2001.01107.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002;9:424-8. [DOI: 10.1046/j.1365-2893.2002.00385.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 2.6] [Reference Citation Analysis]
2 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 13.2] [Reference Citation Analysis]
3 Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol. 2006;101:1516-1523. [PMID: 16863555 DOI: 10.1111/j.1572-0241.2006.00659.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
4 Wang CZ, Li WJ, Tao R, Ye JZ, Zhang HY. Antiviral activity of a nanoemulsion of polyprenols from ginkgo leaves against influenza A H3N2 and hepatitis B virus in vitro. Molecules 2015;20:5137-51. [PMID: 25808155 DOI: 10.3390/molecules20035137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
5 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
6 Durmus O, Tekin L, Carli AB, Cakar E, Acar A, Ulcay A, Dincer U, Kiralp MZ. Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case. Rheumatol Int 2013;33:1345-9. [PMID: 22147111 DOI: 10.1007/s00296-011-2244-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
8 TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509-520. [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
9 Zhong Y, Guo Y, Liu X, Zhang J, Ma T, Shu J, Yang J, Zhang J, Jia Z, Li Z. Serum Glycopatterns as Novel Potential Biomarkers for Diagnosis of Acute-on-Chronic Hepatitis B Liver Failure. Sci Rep 2017;7:45957. [PMID: 28383031 DOI: 10.1038/srep45957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol. 2002;17:409-414. [PMID: 11982721 DOI: 10.1046/j.1440-1746.2002.02767.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
11 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
12 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 949] [Article Influence: 179.3] [Reference Citation Analysis]
13 Peng CY, Chen CB, Lai HC, Su WP, Chuang PH, Wu HD, Jeng LB. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 2010;5:586-96. [PMID: 21442057 DOI: 10.1007/s12072-010-9227-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sun L, Yu J, Zhao Y, Kang P, Li S. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure: Prognostic factors in lamivudine in ACLF. Journal of Gastroenterology and Hepatology 2010;25:583-90. [DOI: 10.1111/j.1440-1746.2009.06089.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
15 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Li C, Zhu B, Lv S, You S, Xin S. Prediction model of the progression of patients with acute deterioration of hepatitis B virus-related chronic liver disease to acute-on-chronic liver failure. Medicine (Baltimore) 2018;97:e11915. [PMID: 30142800 DOI: 10.1097/MD.0000000000011915] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Han T, Liu H, Yu ZL, Li J, Wang L, Xiao SX, Li Y, Yu ML. Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure. J Viral Hepat. 2010;17 Suppl 1:18-23. [PMID: 20586930 DOI: 10.1111/j.1365-2893.2010.01267.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
19 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
20 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774-780. [PMID: 21294143 DOI: 10.1002/hep.24109] [Cited by in Crossref: 167] [Cited by in F6Publishing: 144] [Article Influence: 16.7] [Reference Citation Analysis]
21 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
22 Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426-432. [PMID: 15740488 DOI: 10.1111/j.1440-1746.2004.03534.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
23 Tsubota A, Arase Y, Suzuki Y, Suzuki F, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Benefit of Lamivudine Therapy and Factors Associated with Clinical Outcome in Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B Virus Infection. Intervirology 2004;47:335-41. [DOI: 10.1159/000080877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
24 Yasui S, Fujiwara K, Nakamura M, Miyamura T, Yonemitsu Y, Mikata R, Arai M, Kanda T, Imazeki F, Oda S. Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Viral Hepat. 2015;22:94-102. [PMID: 24750410 DOI: 10.1111/jvh.12258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
25 Shi Y, He J, Wu W, Huang J, Yang Y, Sheng J, Yu L, Chen Z, Jia H. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. Annals of Hepatology 2013;12:364-72. [DOI: 10.1016/s1665-2681(19)30998-6] [Cited by in Crossref: 27] [Article Influence: 3.4] [Reference Citation Analysis]
26 Yuen MF. Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. Hepatol Int 2015;9:373-7. [PMID: 25788180 DOI: 10.1007/s12072-014-9569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Tillmann HL, Klempnauer J, Manns MP. Risks and benefits of nucleosides before and after liver transplantation. Transplant Proc 2003;35:2086-7. [PMID: 14529849 DOI: 10.1016/s0041-1345(03)00674-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256-263. [PMID: 16611192 DOI: 10.1111/j.1365-2893.2005.00695.x] [Cited by in Crossref: 143] [Cited by in F6Publishing: 99] [Article Influence: 9.5] [Reference Citation Analysis]
30 Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013;10:134. [PMID: 23627972 DOI: 10.1186/1743-422X-10-134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
31 Ma K, Guo W, Han M, Chen G, Chen T, Wu Z, Yang D, Huang J, Huang Y, Zhao X, Tian D, Song J, Qi J, Ning Q. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int 2012;6:735-43. [PMID: 26201523 DOI: 10.1007/s12072-012-9344-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
32 Oketani M, Uto H, Ido A, Tsubouchi H. Management of hepatitis B virus-related acute liver failure. Clin J Gastroenterol 2014;7:19-26. [PMID: 26183504 DOI: 10.1007/s12328-013-0447-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]